title: Oral opioid therapy for chronic peripheral and central neuropathic pain.
abstract: BACKGROUND
  Although opioids are commonly used to treat chronic neuropathic pain, there are limited data to guide their use. Few controlled trials have been performed, and many types of neuropathic pain remain unstudied.
  
  
  METHODS
  Adults with neuropathic pain that was refractory to treatment were randomly assigned to receive either high-strength (0.75-mg) or low-strength (0.15-mg) capsules of the potent mu-opioid agonist levorphanol for eight weeks under double-blind conditions. Intake was titrated by the patient to a maximum of 21 capsules of either strength per day. Outcome measures included the intensity of pain as recorded in a diary, the degree of pain relief, quality of life, psychological and cognitive function, the number of capsules taken daily, and blood levorphanol levels.
  
  
  RESULTS
  Among the 81 patients exposed to the study drug, high-strength levorphanol capsules reduced pain by 36 percent, as compared with a 21 percent reduction in pain in the low-strength group (P=0.02). On average, patients in the high-strength group took 11.9 capsules per day (8.9 mg per day) and patients in the low-strength group took close to the 21 allowed (18.3 capsules per day; 2.7 mg per day). Affective distress and interference with functioning were reduced, and sleep was improved, but there were no differences between the high-strength group and the low-strength group in terms of these variables. Noncompletion of the study was primarily due to side effects of the opioid. Patients with central pain after stroke were the least likely to report benefit.
  
  
  CONCLUSIONS
  The reduction in the intensity of neuropathic pain was significantly greater during treatment with higher doses of opioids than with lower doses. Higher doses produced more side effects without significant additional benefit in terms of other outcome measures.
authors.affiliation: Pain Clinical Research Center, Department of Neurology, University of California, San Francisco, School of Medicine, San Francisco, USA.
authors.forename: Michael C
authors.initials: MC
authors.lastname: Rowbotham
authors.forename: Lisa
authors.initials: L
authors.lastname: Twilling
authors.forename: Pamela S
authors.initials: PS
authors.lastname: Davies
authors.forename: Lori
authors.initials: L
authors.lastname: Reisner
authors.forename: Kirk
authors.initials: K
authors.lastname: Taylor
authors.forename: David
authors.initials: D
authors.lastname: Mohr
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000188:drug therapy; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007981:Levorphanol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009437:Neuralgia / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy
chemical_list: D000701:Analgesics, Opioid; D007981:Levorphanol